Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.46 |
| ▸ | EDNRB | P24530 | 2/20 | 0.45 |
| ▸ | EDNRA | P25101 | 2/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409824 | 0.87 | HSD11B1 (0.51) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL7059009 | 0.86 | HSD11B1 (0.47) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL5832114 | 0.86 | HSD11B1 (0.48) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL6624383 | 0.86 | HSD11B1 (0.55) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL5399619 | 0.84 | HSD11B1 (0.47) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL5399624 | 0.84 | HSD11B1 (0.47) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL5399494 | 0.81 | HSD11B1 (0.50) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL3256068 | 0.81 | HSD11B1 (0.51) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL3258766 | 0.81 | HSD11B1 (0.54) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL5389813 | 0.81 | ALDH1A1 (0.47) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| US-7074788-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | CPT1A, HSD11B1, CES1 | HSD11B1 2/4885HSD17B1 5/4885HSD17B2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.